Recent Updates
Recently added Catalysts

GSK Bio's influenza vaccine GSK576389A

Phase 2

Influenza | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jun 8, 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment1,596

FDA Designations

No designations recorded

Clinical trial landscape

GSK Bio's influenza vaccine GSK576389A · 1 trial · 1 indication

Phase 2 1
NCT00532298Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and OverInfluenza
COMPLETED1,596 Analytics
PHASE2COMPLETED
Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over
InfluenzaUnlock trial analytics

Study Endpoints

Primary Endpoints

Haemagglutination Inhibition (HI) Antibody Titers for the H1N1 Vaccine Strain
At Days 0 and 21

Antibody titers were expressed as Geometric mean titers (GMTs). The H1N1 vaccine strains included A/New Caledonia and A/Solomon Islands antigens. A/New Caledonia vaccine strain was administered to both groups receiving the adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season. A/Solomon Islands vaccine strain was administered to both groups receiving the adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season.

Secondary Endpoints

HI Antibody Titers Against Each of the Three Vaccine Strains for the Two Season Formulations
At Days 0 and 21
The Number of Subjects Seroconverted for HI Antibodies Against Each of the Three Vaccine Strains for the Two Season Formulations
At Day 21
HI Antibody Seroconversion Factors
At Day 21
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
GSK576389A- 2006/2007 Season - 1 container GroupEXPERIMENTALSubjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.
GSK576389A - 2006/2007 Season - 2 containers GroupEXPERIMENTALSubjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.
Fluarix 2006/2007 Season GroupACTIVE_COMPARATORSubjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
GSK576389A - 2007/2008 Season - 1 container GroupEXPERIMENTALSubjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.
GSK576389A - 2007/2008 Season - 2 containers GroupEXPERIMENTALSubjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.
Fluarix 2007/2008 Season GroupACTIVE_COMPARATORSubjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.

Interventions

NameTypeDescription
GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]BIOLOGICALSingle dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]BIOLOGICALSingle dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
Fluarix [NH 2006/07 season]BIOLOGICALSingle dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
Fluarix [NH 2007/08 season]BIOLOGICALSingle dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
Unlock Study Design Details

Eligibility Criteria

Age Range65 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites6

Inclusion Criteria: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female aged 65 years or older at the time of the vaccination. * Written informed consent obtained from the subject. * Free of...

Countries:DenmarkEstoniaNorway
Unlock Eligibility Criteria